CBPO - China Biologic Products Holdings, Inc.
| Previous Close | 113.99 |
| Open | 114.08 |
| Bid | 114.27 x 800 |
| Ask | 114.33 x 800 |
| Day's Range | 113.20 - 115.00 |
| 52 Week Range | 60.08 - 115.74 |
| Volume | 473,296 |
| Avg. Volume | 150,710 |
| Market Cap | 4.37B |
| Beta (3Y Monthly) | 0.80 |
| PE Ratio (TTM) | 30.25 |
| EPS (TTM) | 3.78 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 88.14 |
- Benzinga
The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 18) 10X Genomics Inc (NASDAQ: TXG ) (listed its shares ...
- TheStreet.com
China Biologic Shares Soar on Go-Private Takeover Bid
The offer is for $120 a share, a 16% premium to Wednesday's closing stock price for the biopharmaceutical company.
- PR Newswire
China Biologic Announces Receipt of Preliminary Non-Binding "Going Private" Proposal
BEIJING, Sept. 18, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter, dated September 18, 2019, from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd (collectively, the "Buyer Group"), proposing to acquire all of the outstanding ordinary shares of the Company not already owned by the Buyer Group for US$120 per share in cash in a "going private" transaction (the "Transaction").
- GuruFocus.com
5 Guru Stocks With Predictable Businesses
Thor Industries makes the list Continue reading...
Motley FoolChina Biologic Products Inc (CBPO) Q2 2019 Earnings Call Transcript
CBPO earnings call for the period ending June 30, 2019.
- ACCESSWIRE
China Biologic Products Holdings, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2019 / China Biologic Products Holdings, Inc. (NASDAQ: CBPO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August ...
- PR Newswire
China Biologic Reports Financial Results for the Second Quarter of 2019
--2Q19 Total Sales Up 12.7% YoY in USD terms, or 20.4% YoY in RMB terms; Net Income Up 45.5% YoY to $41.6 Million ; Non-GAAP Adjusted Net Income Up 29.1% YoY in RMB terms -- --1H19 Total Sales Up 14.0% ...
- PR Newswire
China Biologic Products to Report Second Quarter 2019 Financial Results
BEIJING , July 26, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- Markit
See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
China Biologic Products Holdings Inc NASDAQ/NGS:CBPOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CBPO are favorable, with net inflows of $776 million. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Motley FoolChina Biologic Products Inc (CBPO) Q1 2019 Earnings Call Transcript
CBPO earnings call for the period ending March 31, 2019.
- Zacks
China Biologic Products (CBPO) Tops Q1 Earnings and Revenue Estimates
China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
China Biologic Products: 1Q Earnings Snapshot
The Beijing-based company said it had net income of 94 cents per share. Earnings, adjusted for non-recurring costs, were $1.11 per share. The biopharmaceutical company posted revenue of $129.8 million ...
- PR Newswire
China Biologic Reports Financial Results for the First Quarter of 2019
--1Q19 Total Sales Up 15.4% YoY in USD terms, or 22.3% YoY in RMB terms; Net Income Up 19.3% YoY to $37.7 Million ; Non-GAAP Adjusted Net Income Up 14.3% YoY in RMB terms -- BEIJING , May 10, 2019 /PRNewswire/ ...
- Zacks
Earnings Preview: China Biologic Products (CBPO) Q1 Earnings Expected to Decline
China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
China Biologic Products to Report First Quarter 2019 Financial Results
BEIJING , April 30, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- Insider Monkey
Is China Biologic Products Inc (CBPO) A Good Stock To Buy According To Hedge Funds?
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Zacks
Analysts Estimate China Biologic Products (CBPO) to Report a Decline in Earnings: What to Look Out for
China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
New Strong Sell Stocks for April 9th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
